



PAGE: 1
12/14/2005

VERIFICATION SUMMARY REPORT

DATE:

PATENT APPLICATION

TIME:

14:54:15

INPUT SEQ: C:\Documents and Settings\user1\My
Documents\WORK_FILES\CLIENTS\Cell-Sci\CS-118.FAMILY\CS-118\SEQ.LIST\CS-
118.ST25.12-14-05.txt

GENERAL INFORMATION SECTION

4,<110> Zimmerman, Daniel H
5, Charoenvit, Yupin
6, Rosenthal, Kenneth
7, Whelan, Mike
9,<120> METHODS FOR TREATING DISEASES OR CONDITIONS WITH
PEPTIDE
10, CONSTRUCTS
12,<130> CS-118
14,<140> US 10/502,328
16,<150> US 60/350,032
17,<151> 2002-01-23
19,<150> US 60/349,982
20,<151> 2002-01-23
22,<150> US 60/349,983
23,<151> 2002-01-23
25,<150> PCT/US03/01816
26,<151> 2003-01-23
28,<160> 28
30,<170> PatentIn version 3.2

ERRORED LINES SECTION

W--> 80 Xaa Gly Gln Glu Glu Lys Ala Gly Val Val Ser Thr Gly Leu Ile
W--> 117 Xaa Glu Thr Val Gly Val Ser Gln Leu Glu Val
W--> 184 Xaa Glu Thr Xaa Gly Xaa Ser Gln Leu Glu Val Gly Gly Gly
W--> 221 Xaa Gly Gln Glu Glu Xaa Ala Gly Val Val Ser Thr Gly Leu Ile
Gly
W--> 257 Xaa Gln Glu Glu Lys Ala Gly Val Val Ser Thr Gly Leu Ile Gly
Gly
W--> 305 Xaa Gly Gln Glu Glu Xaa Ala Gly Val Val Ser Thr Gly Leu Ile
Gly
W--> 341 Xaa Gly Gln Glu Glu Phe Ala Gly Val Val Ser Thr Gly Leu Ile
Gly
W--> 376 Xaa Thr Val Gly Val Ser Gln Leu Glu Val
W--> 407 Xaa Thr Val Gly Val Ser Gln Leu Glu Val
W--> 439 Xaa Thr Val Gly Val Ser Gln Leu Glu
W--> 471 Xaa Thr Val Gly Val Ser Gln Leu
W--> 503 Xaa Thr Val Gly Val Ser Gln
W--> 534 Xaa Thr Val Gly Val Ser
W--> 565 Xaa Thr Val Gly Val
W--> 591 Xaa Gly Gln Glu Glu Lys Ala Gly Val Val Ser Thr Gly Leu Ile
W--> 617 Xaa Gln Glu Glu Lys Ala Gly Val Val Ser Thr Gly Leu Ile
W--> 649 Xaa Gly Gln Glu Glu Lys Ala Gly Gly Val Val Ser Thr Gly Leu
Ile

W--> 719 Xaa Gly Gln Glu Ala Gly Val Val Ser Thr Gly Leu Ile Gly Gly
Gly
W--> 757 Xaa Glu Lys Ala Gly Val Val Ser Thr Gly Leu Ile Gly Gly Gly

PAGE: 2
12/14/2005

VERIFICATION SUMMARY REPORT
PATENT APPLICATION

DATE:
TIME:

14:54:16

INPUT SEQ: C:\Documents and Settings\user1\My
Documents\WORK_FILES\CLIENTS\Cell-Sci\CS-118.FAMILY\CS-118\SEQ.LIST\CS-
118.ST25.12-14-05.txt

W--> 784 Xaa Gly Gln Glu Glu Lys Ala Gly Val Val Ser Thr Gly Leu Ile
Gln
W--> 820 Xaa Gly Gln Glu Glu Lys Ala Gly Val Val Ser Thr Gly Leu Ile
Gln
W--> 870 Xaa Gly Gln Glu Glu Lys Ala Gly Val Val Ser Thr Gly Leu Ile
Gln
W--> 874 Ala Xaa Gly Asp Trp Thr Phe Gln Thr Leu Val
W--> 906 Xaa Lys Ala Gly Val Val Ser Thr Gly Leu Ile Gln Asn Gly Asp
Trp
W--> 947 Xaa Gly Gly Ile Leu Gly Thr Ser Val Val Ala Lys Glu Glu Gln
Gly

STATISTICS SUMMARY

Application Serial Number: US 10/502,328
Alpha or Numeric or Xml: Numeric
Application Class:
Application File Date:
Art Unit:
Software Application: PatentIN3.2
Total Number of Sequences: 28
Total Nucleotides: 0
Total Amino Acids: 428
Number of Errors: 0
Number of Warnings: 25
Number of Corrections: 0

CS-118.ST25.12-14-05
SEQUENCE LISTING

<110> Zimmerman, Daniel H
Charoenvit, Yupin
Rosenthal, Kenneth
Whelan, Mike

<120> METHODS FOR TREATING DISEASES OR CONDITIONS WITH PEPTIDE
CONSTRUCTS

<130> CS-118

<140> US 10/502,328

<150> US 60/350,032
<151> 2002-01-23

<150> US 60/349,982
<151> 2002-01-23

<150> US 60/349,983
<151> 2002-01-23

<150> PCT/US03/01816
<151> 2003-01-23

<160> 28

<170> PatentIn version 3.2

<210> 1
<211> 15
<212> PRT
<213> Artificial Sequence

<220>
<223> Completely synthesized peptide construct

<400> 1

Glu Lys Ala Gly val val Ser Thr Gly Leu Ile Gln Asn Gly Asp
1 5 10 15

<210> 2
<211> 15
<212> PRT
<213> Artificial Sequence

<220>
<223> peptide construct

<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> acetyl, ClAc, BrAc

<220>
<221> MISC_FEATURE
<222> (1)..(1)

<223> X is A or N and when X is A, then A is either cyclohexylalanine or D-alanine

<220>

<221> MISC_FEATURE

<222> (15)..(15)

<223> highly variable fragment wherein isoleucine at 143 and leucine at 159 in contact with CD4 phenylalanine as the 43 residue

<220>

<221> MOD_RES

<222> (15)..(15)

<223> AMIDATION

<400> 2

Xaa	Gly	Gln	Glu	Glu	Lys	Ala	Gly	Val	Val	Ser	Thr	Gly	Leu	Ile
1				5					10					15

<210> 3

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> Completely synthesized peptide construct

<220>

<221> MOD_RES

<222> (1)..(1)

<223> ACETYLATION, Aad

<220>

<221> MISC_FEATURE

<222> (1)..(1)

<223> acetyl, ClAc, BrAc

<220>

<221> MISC_FEATURE

<222> (1)..(1)

<223> X is A or E and when X is A, then A is either cyclohexylalanine or D-alanine

<220>

<221> MOD_RES

<222> (11)..(11)

<223> AMIDATION

<400> 3

Xaa	Glu	Thr	Val	Gly	Val	Ser	Gln	Leu	Glu	Val
1				5					10	

<210> 4

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> completely synthesized peptide construct

<400> 4

Asn Gly Gln Glu Glu Thr Val Gly Val Ser Ser Thr Gln Leu Ile
1 5 10 15

<210> 5

<211> 18

<212> PRT

<213> Artificial Sequence

<220>

<223> completely synthesized peptide construct

<400> 5

Asn Gly Gln Glu Glu Lys Ala Gly Val Val Ser Thr Gly Leu Ile Gly
1 5 10 15

Gly Gly

<210> 6

<211> 14

<212> PRT

<213> Artificial Sequence

<220>

<223> completely synthesized peptide construct

<220>

<221> MISC_FEATURE

<222> (1)..(1)

<223> cyclohexylalanine, D-alanine, acetyl, ClAc, BrAc

<220>

<221> MISC_FEATURE

<222> (1)..(1)

<223> Xaa is an amino acid V, L, I, G or A

<220>

<221> MISC_FEATURE

<222> (4)..(4)

<223> Xaa is an amino acid V, L, I, G or A

<220>

<221> MISC_FEATURE

<222> (6)..(6)

<223> Xaa is an amino acid V, L, I, G or A

<400> 6

Xaa Glu Thr Xaa Gly Xaa Ser Gln Leu Glu Val Gly Gly Gly
1 5 10

<210> 7

<211> 18

<212> PRT
<213> Artificial Sequence

<220>
<223> Completely synthesized peptide construct

<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> acetyl, ClAc, BrAc

<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> X is A or D and when X is A, then A is either cyclohexylalanine or D-alanine

<220>
<221> MISC_FEATURE
<222> (6)..(6)
<223> Xaa is an amino acid V, L, I, G or A

<220>
<221> MOD_RES
<222> (18)..(18)
<223> AMIDATION

<400> 7

Xaa Gly Gln Glu Glu Xaa Ala Gly Val Val Ser Thr Gly Leu Ile Gly
1 5 10 15

Gly Gly

<210> 8
<211> 17
<212> PRT
<213> Artificial Sequence

<220>
<223> Completely synthesized peptide construct

<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> acetyl, ClAc, BrAc

<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> X is A or G and when X is A, then A is either cyclohexylalanine or D-alanine

<220>
<221> MOD_RES
<222> (17)..(17)

<223> AMIDATION

<400> 8

Xaa Gln Glu Glu Lys Ala Gly Val Val Ser Thr Gly Leu Ile Gly Gly
1 5 10 15

Gly

<210> 9

<211> 18

<212> PRT

<213> Artificial Sequence

<220>

<223> Completely synthesized peptide construct

<220>

<221> MISC_FEATURE

<222> (1)..(1)

<223> acetyl, ClAc, BrAc

<220>

<221> MISC_FEATURE

<222> (1)..(1)

<223> X is A or D and when X is A, then A is either cyclohexylalanine or D-alanine

<220>

<221> MISC_FEATURE

<222> (6)..(6)

<223> Xaa is an amino acid V, L, I, G, A, K or F

<220>

<221> MISC_FEATURE

<222> (6)..(6)

<223> analogues such as substituted epsilon amino (methyl, alkyl)
Lysine or hydroxy-Leucine or Leucine

<220>

<221> MOD_RES

<222> (18)..(18)

<223> AMIDATION

<400> 9

Xaa Gly Gln Glu Glu Xaa Ala Gly Val Val Ser Thr Gly Leu Ile Gly
1 5 10 15

Gly Gly

<210> 10

<211> 18

<212> PRT

<213> Artificial Sequence

<220>

<223> Completely synthesized peptide construct

<220>

<221> MISC_FEATURE

<222> (1)..(1)

<223> acetyl, ClAc, BrAc

<220>

<221> MISC_FEATURE

<222> (1)..(1)

<223> X is A or D and when X is A, then A is either cyclohexylalanine or D-alanine

<220>

<221> MOD_RES

<222> (18)..(18)

<223> AMIDATION

<400> 10

Xaa Gly Gln Glu Glu Phe Ala Gly Val Val Ser Thr Gly Leu Ile Gly
1 5 10 15

Gly Gly

<210> 11

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> Completely synthesized peptide construct

<220>

<221> MISC_FEATURE

<222> (1)..(1)

<223> acetyl, ClAc, BrAc

<220>

<221> MISC_FEATURE

<222> (1)..(1)

<223> X is A or E and when X is A, then A is either cyclohexylalanine or D-alanine

<220>

<221> MOD_RES

<222> (10)..(10)

<223> AMIDATION

<400> 11

Xaa Thr Val Gly Val Ser Gln Leu Glu Val
1 5 10

<210> 12
 <211> 10
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> completely synthesized peptide construct

<220>
 <221> MISC_FEATURE
 <222> (1)..(1)
 <223> acetyl, ClAc, BrAc

<220>
 <221> MISC_FEATURE
 <222> (1)..(1)
 <223> X is A or E and when X is A, then A is either cyclohexylalanine or D-alanine

<220>
 <221> MOD_RES
 <222> (10)..(10)
 <223> AMIDATION

<400> 12

Xaa Thr Val Gly Val Ser Gln Leu Glu Val
 1 5 10

<210> 13
 <211> 9
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> completely synthesized peptide construct

<220>
 <221> MISC_FEATURE
 <222> (1)..(1)
 <223> acetyl, ClAc, BrAc

<220>
 <221> MISC_FEATURE
 <222> (1)..(1)
 <223> X is A or E and when X is A, then A is either cyclohexylalanine or D-alanine

<220>
 <221> MOD_RES
 <222> (9)..(9)
 <223> AMIDATION

<400> 13

Xaa Thr Val Gly Val Ser Gln Leu Glu
 1 5

<210> 14
 <211> 8
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Completely synthesized peptide construct

<220>
 <221> MISC_FEATURE
 <222> (1)..(1)
 <223> acetyl, ClAc, BrAc

<220>
 <221> MISC_FEATURE
 <222> (1)..(1)
 <223> X is A or E and when X is A, then A is either cyclohexylalanine or D-alanine

<220>
 <221> MOD_RES
 <222> (8)..(8)
 <223> AMIDATION

<400> 14

Xaa Thr Val Gly Val Ser Gln Leu
 1 5

<210> 15
 <211> 7
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Completely synthesized peptide construct

<220>
 <221> MISC_FEATURE
 <222> (1)..(1)
 <223> acetyl, ClAc, BrAc

<220>
 <221> MISC_FEATURE
 <222> (1)..(1)
 <223> X is A or E and when X is A, then A is either cyclohexylalanine or D-alanine

<220>
 <221> MOD_RES
 <222> (7)..(7)
 <223> AMIDATION

<400> 15

Xaa Thr Val Gly Val Ser Gln
 1 5

<210> 16
 <211> 6
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> completely synthesized peptide construct

<220>
 <221> MISC_FEATURE
 <222> (1)..(1)
 <223> acetyl, ClAc, BrAc

<220>
 <221> MISC_FEATURE
 <222> (1)..(1)
 <223> X is A or E and when X is A, then A is either cyclohexylalanine or D-alanine

<220>
 <221> MOD_RES
 <222> (6)..(6)
 <223> AMIDATION

<400> 16

Xaa Thr Val Gly Val Ser
 1 5

<210> 17
 <211> 5
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> completely synthesized peptide construct

<220>
 <221> MISC_FEATURE
 <222> (1)..(1)
 <223> acetyl, ClAc, BrAc

<220>
 <221> MISC_FEATURE
 <222> (1)..(1)
 <223> X is A or E and when X is A, then A is either cyclohexylalanine or D-alanine

<220>
 <221> MOD_RES
 <222> (5)..(5)
 <223> AMIDATION

<400> 17

Xaa Thr Val Gly Val
 1 5

<210> 18
 <211> 15
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Completely synthesized peptide construct

<220>
 <221> MISC_FEATURE
 <222> (1)..(1)
 <223> acetyl, ClAc, BrAc

<220>
 <221> MISC_FEATURE
 <222> (1)..(1)
 <223> X is A or D and when X is A, then A is either cyclohexylalanine or D-alanine

<400> 18

Xaa Gly Gln Glu Lys Ala Gly Val Val Ser Thr Gly Leu Ile
 1 5 10 15

<210> 19
 <211> 14
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Completely synthesized peptide construct

<220>
 <221> MISC_FEATURE
 <222> (1)..(1)
 <223> acetyl, ClAc, BrAc

<220>
 <221> MISC_FEATURE
 <222> (1)..(1)
 <223> X is A or G and when X is A, then A is either cyclohexylalanine or D-alanine

<400> 19

Xaa Gln Glu Glu Lys Ala Gly Val Val Ser Thr Gly Leu Ile
 1 5 10

<210> 20
 <211> 19
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Completely synthesized peptide construct

<220>

<221> MISC_FEATURE
 <222> (1)..(1)
 <223> acetyl, ClAc, BrAc

<220>
 <221> MISC_FEATURE
 <222> (1)..(1)
 <223> X is A or D and when X is A, then A is either cyclohexylalanine or D-alanine

<220>
 <221> MOD_RES
 <222> (19)..(19)
 <223> AMIDATION

<400> 20

xaa Gly Gln Glu Glu Lys Ala Gly Gly Val Val Ser Thr Gly Leu Ile
 1 5 10 15

Gly Gly Gly

<210> 21
 <211> 17
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Completely synthesized peptide construct

<220>
 <221> MISC_FEATURE
 <222> (7)..(8)
 <223> gamma aminobutyric acid (gaba) or 3 amino propanoic acid (apa)

<220>
 <221> MOD_RES
 <222> (17)..(17)
 <223> AMIDATION

<400> 21

Asp Gly Gln Glu Glu Lys Ala Val Val Ser Thr Gly Leu Ile Gly Gly
 1 5 10 15

Gly

<210> 22
 <211> 16
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Completely synthesized peptide construct

<220>
 <221> MISC_FEATURE
 <222> (1)..(1)
 <223> acetyl, ClAc, BrAc

<220>
 <221> MISC_FEATURE
 <222> (1)..(1)
 <223> X is A or D and when X is A, then A is either cyclohexylalanine or D-alanine

<220>
 <221> MISC_FEATURE
 <222> (5)..(5)
 <223> GG is replaced with gamma aminobutyric acid (gaba) or 3 amino propanoic acid (apa)

<220>
 <221> MOD_RES
 <222> (16)..(16)
 <223> AMIDATION

<400> 22

Xaa Gly Gln Glu Ala Gly Val Val Ser Thr Gly Leu Ile Gly Gly Gly
 1 5 10 15

<210> 23
 <211> 15
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Completely synthesized peptide construct

<220>
 <221> MISC_FEATURE
 <222> (1)..(1)
 <223> GG is replaced with gamma aminobutyric acid (gaba) or 3 amino propanoic acid (apa)

<220>
 <221> MISC_FEATURE
 <222> (1)..(1)
 <223> acetyl, ClAc, BrAc

<220>
 <221> MISC_FEATURE
 <222> (1)..(1)
 <223> X is A or E and when X is A, then A is either cyclohexylalanine or D-alanine

<220>
 <221> MOD_RES
 <222> (15)..(15)
 <223> AMIDATION

<400> 23

xaa Glu Lys Ala Gly val val Ser Thr Gly Leu Ile Gly Gly Gly
 1 5 10 15

<210> 24
 <211> 26
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Completely synthesized peptide construct

<220>
 <221> MISC_FEATURE
 <222> (1)..(1)
 <223> acetyl, ClAc, BrAc

<220>
 <221> MISC_FEATURE
 <222> (1)..(1)
 <223> X is A or N and when X is A, then A is either cyclohexylalanine or D-alanine

<400> 24

xaa Gly Gln Glu Glu Lys Ala Gly val val Ser Thr Gly Leu Ile Gln
 1 5 10 15

Asn Gly Asp Trp Thr Phe Gln Thr Leu Val
 20 25

<210> 25
 <211> 26
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Completely synthesized peptide construct

<220>
 <221> MISC_FEATURE
 <222> (1)..(1)
 <223> acetyl, ClAc, BrAc

<220>
 <221> MISC_FEATURE
 <222> (1)..(1)
 <223> X is A or N and when X is A, then A is either cyclohexylalanine or D-alanine

<220>
 <221> MOD_RES
 <222> (26)..(26)
 <223> AMIDATION

<400> 25

CS-118.ST25.12-14-05

xaa	Gly	Gln	Glu	Glu	Lys	Ala	Gly	Val	Val	Ser	Thr	Gly	Leu	Ile	Gln
1			5					10						15	

Asp	Gly	Asp	Trp	Thr	Phe	Gln	Thr	Leu	Val
		20					25		

<210> 26
 <211> 27
 <212> PRT
 <213> Artificial sequence

<220>
 <223> completely synthesized peptide construct

<220>
 <221> MISC_FEATURE
 <222> (1)..(1)
 <223> acetyl, ClAc, BrAc

<220>
 <221> MISC_FEATURE
 <222> (1)..(1)
 <223> X is A or N and when X is A, then A is either cyclohexylalanine or D-alanine

<220>
 <221> misc_feature
 <222> (18)..(18)
 <223> xaa can be any naturally occurring amino acid

<220>
 <221> MISC_FEATURE
 <222> (19)..(19)
 <223> hydrophilic aminobutanoic acid (aba)

<220>
 <221> MISC_FEATURE
 <222> (19)..(19)
 <223> S or not present

<220>
 <221> MOD_RES
 <222> (19)..(19)
 <223> AMIDATION

<400> 26

xaa	Gly	Gln	Glu	Glu	Lys	Ala	Gly	Val	Val	Ser	Thr	Gly	Leu	Ile	Gln
1			5					10						15	

Ala	xaa	Gly	Asp	Trp	Thr	Phe	Gln	Thr	Leu	Val
			20					25		

<210> 27
 <211> 22
 <212> PRT
 <213> Artificial Sequence

<220>
<223> Completely synthesized peptide construct

<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> acetyl, ClAc, BrAc

<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> X is A or E and when X is A, then A is either cyclohexylalanine or D-alanine

<220>
<221> MOD_RES
<222> (22)..(22)
<223> AMIDATION

<400> 27

Xaa Lys Ala Gly val val Ser Thr Gly Leu Ile Gln Asn Gly Asp Trp
1 5 10 15

Thr Phe Gln Thr Leu Val
20

<210> 28
<211> 17
<212> PRT
<213> Artificial Sequence

<220>
<223> Completely synthesized peptide construct

<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> acetyl, ClAc, BrAc

<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> X is A or G and when X is A, then A is either cyclohexylalanine or D-alanine

<220>
<221> MISC_FEATURE
<222> (10)..(11)
<223> gamma aminobutyric acid (gaba) or 3 amino propanoic acid (apa)

<220>
<221> MOD_RES
<222> (17)..(17)
<223> AMIDATION

<400> 28

CS-118.ST25.12-14-05

Xaa Gly Gly Ile Leu Gly Thr Ser Val Val Ala Lys Glu Glu Gln Gly
1 5 10 15

Asp